Konishi H
Kyoto Prefectural University of Medicine
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Konishi H.
British Journal of Cancer | 2012
Konishi H; Daisuke Ichikawa; Komatsu S; Atsushi Shiozaki; Masahiro Tsujiura; Hiroki Takeshita; Morimura R; H Nagata; Tomohiro Arita; Tsutomu Kawaguchi; S Hirashima; Hitoshi Fujiwara; Kazuma Okamoto; Eigo Otsuji
Background:Recently, it was reported that plasma microRNAs (miRNAs) are low-invasive useful biomarkers for cancer. We attempted to isolate gastric cancer (GC)-associated miRNAs comparing pre- and post-operative paired plasma, thereby excluding the possible effects of individual variability.Methods:This study was divided into four steps: (1) microarray analysis comparing pre- and post-operative plasma; (2) validation of candidate miRNAs by quantitative RT–PCR; (3) validation study of selected miRNAs using paired plasma; and (4) comparison of the levels of selected miRNAs in plasma between healthy controls and patients.Results:From the results of microarray analysis, nine candidate miRNAs the levels of which were markedly decreased in post-operative plasma were selected for further studies. After confirmation of their post-operative marked reduction, two candidate miRNAs, miR-451 and miR-486, were selected as plasma biomarkers, considering the abundance in plasma, and marked decrease in post-operative samples. In validation, the two miRNAs were found to decrease in post-operative plasma in 90 and 93% of patients (both P<0.01). In comparison with healthy controls, the levels of both miRNAs were found to be significantly higher in patients, and the area under the curve values were high at 0.96 and 0.92.Conclusion:Plasma miR-451 and miR-486 could be useful blood-based biomarkers for screening GC.
British Journal of Cancer | 2014
Shuhei Komatsu; Daisuke Ichikawa; Shoji Hirajima; Tsutomu Kawaguchi; Mahito Miyamae; Wataru Okajima; Takuma Ohashi; Tomohiro Arita; Konishi H; Atsushi Shiozaki; Hitoshi Fujiwara; Kazuma Okamoto; Nobuaki Yagi; Eigo Otsuji
Background:Recent studies have demonstrated that microRNAs are stably detectable in plasma/serum because of their binding to specific proteins or being packaged in secretory particles. This study was designed to detect novel microRNAs in plasma for cancer detection and monitoring using microRNA array-based approaches in oesophageal squamous cell carcinoma (ESCC) patients.Methods:Through the integration of two Toray 3D-Gene microRNA array-based approaches to compare plasma microRNA levels between ESCC patients and healthy volunteers and between preoperative and postoperative ESCC patients, we identified a novel plasma biomarker in ESCC.Results:(1) Eight upregulated and common microRNAs (miR-15b, 16, 17, 25, 19b, 20a, 20b, and 106a) were selected using two high-resolution microRNA array approaches. (2) Test-scale analyses by quantitative RT–PCR validated a significant higher levels of plasma miR-19b (P=0.0020) and miR-25 (P=0.0030) in ESCC patients than controls. However, a significant correlation was observed between plasma miR-19b levels and concentrations of red blood cells (P=0.0073) and haemoglobin (P=0.0072). (3) miR-25 expression was found to be significantly higher in ESCC tissues (P=0.0157) and ESCC cell lines (P=0.0093) than in normal tissues and fibroblasts. (4) In a large-scale validation analysis, plasma miR-25 levels were significantly higher in 105 preoperative (P<0.0001) ESCC patients who underwent curative oesophagectomy and 20 superficial ESCC patients who underwent endoscopic resection (P<0.0001) than in 50 healthy volunteers. (5) Plasma miR-25 levels were significantly reduced in postoperative samples than in preoperative samples (P<0.0005) and were significantly increased during ESCC recurrences (P=0.0145).Conclusions:Plasma miR-25 might be a clinically useful biomarker for cancer detection and the monitoring of tumour dynamics in ESCC patients.
British Journal of Cancer | 2013
Yukihisa Nishimura; Shuhei Komatsu; Daisuke Ichikawa; H Nagata; Shoji Hirajima; Hiroki Takeshita; Tsutomu Kawaguchi; Tomohiro Arita; Konishi H; Kingo Kashimoto; Atsushi Shiozaki; Hitoshi Fujiwara; Kazuma Okamoto; Hitoshi Tsuda; Eigo Otsuji
Background:Several studies have demonstrated that YWHAZ (14-3-3ζ), included in the 14-3-3 family of proteins, has been implicated in the initiation and progression of cancers. We tested whether YWHAZ acted as a cancer-promoting gene through its activation/overexpression in gastric cancer (GC).Methods:We analysed 7 GC cell lines and 141 primary tumours, which were curatively resected in our hospital between 2001 and 2003.Results:Overexpression of the YWHAZ protein was frequently detected in GC cell lines (six out of seven lines, 85.7%) and primary tumour samples of GC (72 out of 141 cases, 51%), and significantly correlated with larger tumour size, venous and lymphatic invasion, deeper tumour depth, and higher pathological stage and recurrence rate. Patients with YWHAZ-overexpressing tumours had worse overall survival rates than those with non-expressing tumours in both intensity and proportion expression-dependent manner. YWHAZ positivity was independently associated with a worse outcome in multivariate analysis (P=0.0491, hazard ratio 2.3 (1.003–5.304)). Knockdown of YWHAZ expression using several specific siRNAs inhibited the proliferation, migration, and invasion of YWHAZ-overexpressing GC cells. Higher expression of the YWHAZ protein was significantly associated with the lower expression of miR-375 in primary GC tissues (P=0.0047).Conclusion:These findings suggest that YWHAZ has a pivotal role in tumour cell proliferation through its overexpression, and highlight its usefulness as a prognostic factor and potential therapeutic target in GC.
British Journal of Cancer | 2015
Shuhei Komatsu; Daisuke Ichikawa; Shoji Hirajima; H Nagata; Yukihisa Nishimura; Tsutomu Kawaguchi; Mahito Miyamae; Wataru Okajima; Takuma Ohashi; Konishi H; Atsushi Shiozaki; Hitoshi Fujiwara; Koichi Okamoto; Hitoshi Tsuda; Issei Imoto; Johji Inazawa; Eigo Otsuji
Background:SET and MYND domain-containing protein 2 (SMYD2) is a lysine methyltransferase for histone H3, p53 and Rb and inhibits their transactivation activities. In this study, we tested whether SMYD2 (1q42) acts as a cancer-promoting factor by being overexpressed in gastric cancer.Methods:We analysed 7 gastric cancer cell lines and 147 primary tumor samples of gastric cancer, which were curatively resected in our hospital.Results:SET and MYND domain-containing protein 2 was detected in these cell lines (five out of seven cell lines; 71.4%) and primary tumor samples (fifty-six out of one hundred and forty-seven cases; 38.1%). Knockdown of SMYD2 using specific small interfering RNA inhibited proliferation, migration and invasion of SMYD2-overexpressing cells in a TP53 mutation-independent manner. Overexpression of SMYD2 protein correlated with larger tumor size, more aggressive lymphatic invasion, deeper tumor invasion and higher rates of lymph node metastasis and recurrence. Patients with SMYD2-overexpressing tumours had a worse overall rate of survival than those with non-expressing tumours (P=0.0073, log-rank test) in an intensity and proportion score-dependent manner. Moreover, multivariate analysis demonstrated that SMYD2 was independently associated with worse outcome (P=0.0021, hazard ratio 4.25 (1.69–10.7)).Conclusions:These findings suggest that SMYD2 has a crucial role in tumor cell proliferation by its overexpression and highlight its usefulness as a prognostic factor and potential therapeutic target in gastric cancer.
Diseases of The Esophagus | 2016
Hitoshi Fujiwara; Atsushi Shiozaki; Konishi H; Komatsu S; Takeshi Kubota; Daisuke Ichikawa; Kazuma Okamoto; Morimura R; Yasutoshi Murayama; Yoshiaki Kuriu; Hisashi Ikoma; Masayoshi Nakanishi; Sakakura C; Eigo Otsuji
Laparoscopic transhiatal esophagectomy is a minimally invasive approach for esophageal cancer. However, a transhiatal procedure has not yet been established for en bloc mediastinal dissection. The purpose of this study was to present our novel procedure, hand-assisted laparoscopic transhiatal esophagectomy, with a systematic procedure for en bloc mediastinal dissection. The perioperative outcomes of patients who underwent this procedure were retrospectively analyzed. Transhiatal subtotal mobilization of the thoracic esophagus with en bloc lymph node dissection distally from the carina was performed according to a standardized procedure using a hand-assisted laparoscopic technique, in which the operator used a long sealing device under appropriate expansion of the operative field by hand assistance and long retractors. The thoracoscopic procedure was performed for upper mediastinal dissection following esophageal resection and retrosternal stomach roll reconstruction, and was avoided based on the nodal status and operative risk. A total of 57 patients underwent surgery between January 2012 and June 2013, and the transthoracic procedure was performed on 34 of these patients. In groups with and without the transthoracic procedure, total operation times were 370 and 216 minutes, blood losses were 238 and 139 mL, and the numbers of retrieved nodes were 39 and 24, respectively. R0 resection rates were similar between the groups. The incidence of recurrent laryngeal nerve palsy was significantly higher in the group with the transthoracic procedure, whereas no significant differences were observed in that of pneumonia between these groups. The hand-assisted laparoscopic transhiatal method, which is characterized by a systematic procedure for en bloc mediastinal dissection supported by hand and long device use, was safe and feasible for minimally invasive esophagectomy.Laparoscopic transhiatal esophagectomy is a minimally invasive approach for esophageal cancer. However, a transhiatal procedure has not yet been established for en bloc mediastinal dissection. The purpose of this study was to present our novel procedure, hand-assisted laparoscopic transhiatal esophagectomy, with a systematic procedure for en bloc mediastinal dissection. The perioperative outcomes of patients who underwent this procedure were retrospectively analyzed. Transhiatal subtotal mobilization of the thoracic esophagus with en bloc lymph node dissection distally from the carina was performed according to a standardized procedure using a hand-assisted laparoscopic technique, in which the operator used a long sealing device under appropriate expansion of the operative field by hand assistance and long retractors. The thoracoscopic procedure was performed for upper mediastinal dissection following esophageal resection and retrosternal stomach roll reconstruction, and was avoided based on the nodal status and operative risk. A total of 57 patients underwent surgery between January 2012 and June 2013, and the transthoracic procedure was performed on 34 of these patients. In groups with and without the transthoracic procedure, total operation times were 370 and 216 minutes, blood losses were 238 and 139 mL, and the numbers of retrieved nodes were 39 and 24, respectively. R0 resection rates were similar between the groups. The incidence of recurrent laryngeal nerve palsy was significantly higher in the group with the transthoracic procedure, whereas no significant differences were observed in that of pneumonia between these groups. The hand-assisted laparoscopic transhiatal method, which is characterized by a systematic procedure for en bloc mediastinal dissection supported by hand and long device use, was safe and feasible for minimally invasive esophagectomy.
Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi | 2006
Shojiro Kikuchi; Yoshitaka Nakamura; Tokunari Okayama; Konishi H; Yoshihiro Kitagawa; Tomoyuki Tagi; Toshiya Ochiai; Satoru Yasukawa; Hisakazu Yamagishi
症例は80歳の女性で, 平成16年5月に軽度の下痢・腹痛・右下腹部腫瘤のために近医を受診した. 腹部CT, X線検査にて右下腹部に手拳大の腹壁浸潤を疑う嚢胞性腫瘤を認めた. 腫瘤は充実性成分を持ち, CT・MRI・FDG-PET・腫瘍マーカーなどより「虫垂癌・腹膜播種」と考えた. 手術時診断も同様であったが, 病理組織学的診断は乳頭状腺癌がclear cell carcinoma成分を持つ非常にまれな原発性腹膜嚢胞性腺癌であり, 中腎傍管 (paramesonephric duct/mullerian) 由来であると考えられた. 文献的には非常に予後の悪い癌であるが, 本症例においては外科的切除に加えてCDDP+TS-1の術後化学療法にて再発腫瘍の縮小を認め, 手術後17か月で外来通院治療中である.
Anticancer Research | 2009
Konishi H; Shojiro Kikuchi; Toshiya Ochiai; Hisashi Ikoma; Takeshi Kubota; Daisuke Ichikawa; Hitoshi Fujiwara; Kazuma Okamoto; Chouhei Sakakura; Teruhisa Sonoyama; Yukihito Kokuba; Hiroyuki Sasaki; Takeshi Matsui; Eigo Otsuji
Journal of Cancer Research and Clinical Oncology | 2007
Toshiya Ochiai; Teruhisa Sonoyama; Shojiro Kikuchi; Tokunari Okayama; Konishi H; Masahiro Kitagawa; Tomoyuki Tagi; Yuji Ueda; Eigo Otsuji
Ejso | 2017
Komatsu S; Daisuke Ichikawa; M. Nishimura; Toshiyuki Kosuga; Kazuma Okamoto; Konishi H; Atsushi Shiozaki; Hitoshi Fujiwara; Eigo Otsuji
Hepato-gastroenterology | 2007
Toshiya Ochiai; Teruhisa Sonoyama; Shojiro Kikuchi; Konishi H; Masahiro Kitagawa; Tokunari Okayama; Daisuke Ichikawa; Yuji Ueda; Eigo Otsuji; Hisakazu Yamagishi